Vencanna Ventures Inc (VENCF) Fair Value & Analysis
Healthcare · US · Market cap $223K
Vencanna Ventures Inc
VENCF · US
Fair value as of: Jun 26, 2026
From 1 valuation models · updated 7 days ago
Fair value updated Jun 26, 2026 — revised from $0.0011 to $0.0010 (−8.8%) since Jun 25, 2026.
Price vs Fair Value (2 months)
2‑month range $0.0009 – $0.0010 · fair‑value band $0.0010 – $0.0010 · the $0.0010 price screens below the $0.0010 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Vencanna Ventures Inc (VENCF) currently trades at $0.0010, while our model-based Fair Value estimate is $0.0010 — implying the stock looks roughly 0.3% undervalued today. We read business quality at 49/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Over the trailing twelve months, Vencanna Ventures Inc generated revenue of $2.0M at a net margin of -91.1%. Revenue declined 56.7% year over year. Fundamentals as of Jun 26, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Vencanna Ventures Inc. is formerly known as The Cannavative Group LLC is a venture capital firm specializing in seed/startups and early venture. It prefers to invest in cannabis sectors. The firm prefers to invest in companies based in United States, North America and beyond. Vencanna Ventures Inc. is based in Calgary, Canada.
Revenue & earnings trend
FY2022 – FY2025 · reported fiscal years
Vencanna Ventures Inc reported revenue of $4.0M in FY2025 versus $0 in FY2022. Reported net income was −$3.9M in FY2025.
Is VENCF fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,786 | ₹991.46 | -44% |
| Zoetis Inc Z1TS34 | R$25.93 | R$19.70 | -24% |
| Hansoh Pharmaceutical Group 3692 | HK$29.30 | HK$23.90 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
| Swedish Orphan Biovitrum AB SOBI | kr 435.00 | kr 285.77 | -34% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Vencanna Ventures Inc (VENCF) undervalued?
What is the fair value of VENCF?
What is the quality score of VENCF?
What is the revenue of Vencanna Ventures Inc (VENCF)?
What is the net profit margin of VENCF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.